Possible

Misidentification of Haemophilus aphrophilus as Pasteurella gallinarum
Sir-Recent reports by Al Fadel Saleh et al. [1] and Arashima et al. [2] have drawn attention to Pasteurella gallinarum as a possible cause of disease in humans. Since, to our knowledge, there have been no previous reports of isolation of P. gallinarum from humans, these 2 reports raise suspicion that misidentification of a strain has occurred. Several years ago, a strain (P 961) isolated from a blood sample obtained from a patient with probable endocarditis was sent to an experienced veterinary (poultry) bacteriologist as part of an exchange of strains. The veterinary bacteriologist identified the strain as catalase-negative P. gallinarum. However, an experienced nonveterinary medical bacteriologist (W.F.) later identified the strain as Haemophilus aphrophilus. P. gallinarum is well known to veterinary bacteriologists, whereas H. aphrophilus is better known to nonveterinary medical bacteriologists; therefore, it is probable that an unknown isolate will be identified as belonging to the taxon best known to the particular bacteriologist who is making the identification.
The misidentification of P. gallinarum as H. aphrophilus may have occurred because the 2 strains have few differentiating characteristics, and because they are seldom included in the same identification table in textbooks and in other reference publications (the work of Kilian and Frederiksen [3] is one exception). Catalase and gas from glucose are the main findings that allow for differentiation of P. gallinarum and H. aphrophilus (table 1) .
Al Fadel Saleh et al. [1] indicated that they characterized the investigated strain as P. gallinarum by use of the API 20E and API 20NE systems (BioMerieux), and on the basis of a positive result for catalase and a negative result for gas from glucose. Arashima et al. [2] indicated that they identified the P. gallinarum bacteria on the basis of "their biochemical properties."
The phenotypical description of the strain mentioned by Al Fadel Saleh et al. is compatible with that of P. gallinarum; however, P. gallinarum is not included in the API 20NE system database, which makes use of this system of dubious benefit. We have been told by BioMerieux (K. Astrup, personal communication) that strains of P. gallinarum have produced reactions that have led to the octal codes 5020004 and 5000004 (i.e., on the basis of a reduction in NO 3 , a positive result for acid from glucose, a positive or negative result for p-nitrophenyl-b-Dgalactopyranoside [PNPG] , and a positive result for oxidase), reactions that are characteristic of both P. gallinarum and H. aphrophilus.
To elucidate the matter, we tested 3 [4] ; P 404 and P 961, human isolates from blood; and P 228 and P 230, human isolates from actinomycotic lesions. PNPG, p-nitrophenyl-b-D-galactopyranoside; ϩ, positive result; Ϫ, negative result.
strains of both species (including the type strains), by means of conventional testing and by use of the API 20NE system. We also tested 3 strains of Actinobacillus actinomycetemcomitans, a species that is considered to be similar to H. aphrophilus. The results of these tests are shown in tables 2 and 3 (only tests that gave different results among the strains or that contributed to the octal code are shown).
When conventional testing was done, the o-nitrophenyl-b-D-galactopyranoside (ONPG), glucose, and lactose tests distinguished P. gallinarum from H. aphrophilus, and when testing was done with use of the API 20NE system, the PNPG test allowed for differentiation of the 2 strains. A. actinomycetemcomitans can be distinguished from H. aphrophilus according to the results of tests for ONPG, sucrose, and lactose; the CO 2 dependency of A. actinomycetemcomitans is an extra aid for identification of the species. When testing was done with use of the API 20NE system, A. actinomycetemcomitans strains produced the same reactions as did P. gallinarum strain P 190. Because some P. gallinarum strains produce acid from lactose and are positive for b-galactosidase, use of the conventional ONPG test or the PNPG test in the API 20NE system are not sufficient for differentiation of P. gallinarum and H. aphrophilus, regardless of whether we found our 3 P. gallinarum strains to test negative for these features.
It seems plausible that the strain described by Al Fadel Saleh et al. could be a P. gallinarum strain, since it was reported to test positive for catalase and negative for gas from glucose. Because Arashima et al. provided no information about the strain that they reported, it remains unclear whether their strain really was a P. gallinarum strain.
We conclude that use of the API 20NE system does not allow for differentiation between P. gallinarum, H. aphrophilus, and A. actinomycetemcomitans. The 3 species can be identified by use of conventional tests, although with difficulty, since presence of catalase may be the only finding that distinguishes P. gallinarum from H. aphrophilus. When characterized by 16S rRNA sequencing, P. gallinarum and H. aphrophilus are widely separated (dissimilarity, 17%) [5] , which indicates that they are indeed separate species.
When unusual strains are found in unusual circumstances, we strongly recommend that either (1) the strains be sent to a competent reference laboratory, where they can be compared with authentic strains of suspected species, or (2) the investigators obtain reference strains and make this comparison themselves. H. aphrophilus is well known as an organism that may be found in humans and that may cause endocarditis; it has not been found in other hosts. P. gallinarum is well known to poultry bacteriologists, and its isolation from human clinical material should be questioned until such isolation can be rigorously proven. If these strains are kept, they should be sent to an experienced reference laboratory (e.g., the 
Reply
Sir-In response to the letter of Drs. Frederiksen and Tønning [1] , we note that ATCC 13361 is used as the standard strain for Pasteurella gallinarum identification. The biological features of the strains of ATCC 13361 and P. gallinarum isolated from our patient were the same. Both types of bacteria were gram-negative rods that were unable to grow on MacConky agar, and neither of them produced indole. Test results for the following were positive: oxidase, catalase, glucose, trehalose, and maltose; test results for the following were negative: ornithine, decarboxylose, urease, mannitol, sorbitol, lactose, d-xylose, and l-arabinose.
Long-Term High-Dose Acyclovir and AIDSRelated Non-Hodgkins Lymphoma
Sir-In their recent article, Fong et al. [1] report that long-term administration of high-dose acyclovir may protect against development of AIDS-related non-Hodgkin's lymphoma (NHL In further unpublished analyses, we found that 44% of cases and 36% of controls had received any acyclovir during the year prior to diagnosis ( ). There was P p .08 no significant association between acyclovir or ganciclovir use and the risk of individual NHL subtypes (immunoblastic, Burkitt's, or primary CNS lymphoma).
We believe that differences in study design may explain these discrepant results. Fong et al. [1] acknowledge that the use of prolonged high-dose acyclovir has changed over time, related to study findings in 1993 that high-dose acyclovir in combination with zidovudine prolonged life in people with AIDS [3] . Specifically, we believe that the use of high-dose acyclovir increased in the early 1990s and then decreased when effective antiretroviral therapies became available. These changes in use of acyclovir over time mean that year of diagnosis of NHL will confound relationships between acyclovir and NHL risk. Unlike our study, in which cases and controls were matched for date of diagnosis ‫6ע(‬ months), the study by Fong et al. [1] does not appear to be matched for date of diagnosis. A reanalysis of their results adjusted for year of diagnosis would address this concern.
Fong et al. [1] suggest that randomized controlled trials of anti-herpesvirus agents are warranted, to further investigate this hypothesis. In fact, several large trials of acyclovir have been published, and a meta-analysis of these trials in a total of 1792 patients found that high-dose acyclovir did not protect from death due to NHL (OR, 0.83; 95% CI, 0.35-1.92) [4] . Individual randomized controlled trials of ganciclovir have shown that systemic therapy decreases the risk of development of Kaposi's sarcoma [5] but not NHL [6] . A meta-analysis of ganciclovir trials is warranted, to further investigate whether systemic therapy may affect NHL risk.
The prevention of NHL in people with HIV infection is of increasing importance, since this malignancy is comprising an increasing proportion of AIDS-related illnesses [7] . However, we conclude that currently there are insufficient data to justify new randomized controlled trials of antiherpesviral agents to prevent NHL.
